Skip to main content

Biogen expects slow Alzheimer's drug uptake, may reset price

By Bloomberg  
   June 23, 2021

Biogen Inc. expects gradual uptake of its new Alzheimer’s disease drug in the U.S. and said it would consider adjusting its $56,000-a-year price if the medication is taken by more patients than anticipated.

Full story

Get the latest on healthcare leadership in your inbox.